OBSAinactive
ObsEva SA
Biopharma developer (SEC filing verified)·Phase 3
OBSA evidence brief
What we can confirm
No verified snapshot fields are available yet.
What it means
The company data is ready for cross-source review; unsupported conclusions remain unknown.
What to watch
Watch the next source-backed data update.
BioSniper AIPage evidence connected
Prepared research question
What matters most for OBSA—catalysts, financial risk and supporting evidence?
Run cited research
Traceable citations · Unknowns marked
4.9/10
BioSniper Score
Based on 4 of 6 signals
Financial data as of Dec 31, 2022.
Tracking 1 pipeline candidate · 2 clinical trials for ObsEva SA.
Run ObsEva SA through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ObsEva SA facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
Cash Runway0.6
2.0 months
Financial Health7.1
D/E 0.95
Pipeline Maturity8.5
Lead: Phase 3
Pipeline Breadth3.3
1 candidate
Catalyst MomentumN/A
No upcoming catalysts tracked
Insider SignalN/A
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.